Tradestie Institutional Equity Comparison Engine
OKUR vs AVIR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVIR Overall Edge
AVIR Captures Institutional Edge (2โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Atea Pharmaceuticals, Inc. Common Stock (AVIR) driven by superior Momentum & Technical, Options & Structure. Fundamentally, OKUR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AVIR at N/M Forward P/E and 0.0% operating margin (+295.2% YoY). In options structure, OKUR sits in SURGE (100th %ile IV; Dealer Gamma Walls on Pro) against AVIR sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
OKUR N/M vs AVIR N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +295.2%
Momentum & Technical Winner
AVIR
1Y -2.2% vs +25.7% ยท 52W Pos 20% vs 29%
Options & Structure Winner
AVIR
SURGE (100th %ile IV) vs BREAKDOWN (100th %ile IV)
OKUR
NASDAQ
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap
$113.7M
1M Return
+4.65%
1Y Return
-2.17%
Forward P/E
N/M
Unified AI Score
36.0 / 100
SELL
Tech 20.0
Fund 46.0
Flow 64.0
Mom 60.0
AVIR
NASDAQ
Atea Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$3.96
+0.76% 1D
Market Cap
$315.6M
1M Return
-2.22%
1Y Return
+25.71%
Forward P/E
N/M
Unified AI Score
44.0 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 67.0
Mom 68.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
OKUR -2.17%
AVIR +25.71%
Spread: +27.88 pp (AVIR Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
OKUR TTM Op. Margin: 0.0%
AVIR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs AVIR. Trailing 12-month operating profitability (OKUR 0.0% vs AVIR 0.0%) and valuation multiples (OKUR N/M vs AVIR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OKUR | AVIR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $113.7M | $315.6M | Larger Scale | AVIR |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +295.2% | Higher Growth | AVIR |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -55.2% | -63.2% | Higher ROE | OKUR |
| 52-Week Range Position Momentum | 20% ($2โ$5) | 29% ($3โ$6) | Stronger Trend | AVIR |
| Beta / 30D Volatility Risk Regime | 0.96ฮฒ ยท 100% Vol | 0.96ฮฒ ยท 48% Vol | Lower Realized Risk | AVIR |
| Unified Institutional Score Composite Signal | 36.0 / 100 (SELL) | 44.0 / 100 (HOLD) | Higher Composite | AVIR |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full OKUR vs AVIR Buy Guide
OKUR
SURGE
8d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
AVIR
BREAKDOWN
54d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither OKUR nor AVIR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.